De-risking the discovery and development of new drugs from bench to clinic

被引：0
|
作者：
Ilyin, SE [1 ]
机构：
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Bioinformat Translat Technol Grp Leader, Spring House, PA 19477 USA
来源：
CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2005年 / 5卷 / 11期
关键词：
D O I：
10.2174/156802605774297083
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：1031 / 1031
页数：1
相关论文
共 50 条
  • [1] De-Risking Clinical Development
    Greene, Douglas A.
    [J]. GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2012, 32 (03): : 38 - 39
  • [2] De-Risking Drug Discovery with ADDME - Avoiding Drug Development Mistakes Early
    Tsaioun, Katya
    Jacewicz, Mary
    [J]. ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2009, 37 : 47 - 55
  • [3] THE THAWSTAR™ AUTOMATED CELL THAWING PLATFORM: DE-RISKING THAWING FROM RESEARCH TO THE CLINIC
    Kunkel, E. J.
    Schryver, B.
    Thompson, M.
    Ehrhardt, R.
    [J]. CYTOTHERAPY, 2016, 18 (06) : S83 - S84
  • [4] Developability assessment as an early de-risking tool for biopharmaceutical development
    Zurdo, Jesus
    [J]. PHARMACEUTICAL BIOPROCESSING, 2013, 1 (01) : 29 - 50
  • [5] A New Landscape: Taking Advantage of the Evolving De-Risking Market
    Seymour, Matthew
    [J]. JOURNAL OF INVESTING, 2018, 27 : 30 - 32
  • [6] Impact of hemolysis on multiomic pancreatic cancer biomarker discovery: De-risking precision medicine biomarker development
    Kiebish, Michael A.
    Shah, Punit
    Bussberg, Valerie
    Tolstikov, Vladimir
    Searfoss, Rick
    Ofori-Mensa, Kennedy
    Grund, Eric M.
    Darkwah, Abena
    Chen, Emily Y.
    Greenwood, Bennett
    Ntoso, Ellaine Adu
    Rodrigues, Leonardo
    Liu, Mia
    Granger, Elder
    Bountra, Chas
    Sarangarajan, Rangaprasad
    Moser, A. J.
    Narain, Niven R.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [7] Bank De-Risking Impacts on Finance and Development. The Case of Romania
    Georgescu, George
    [J]. ISSUES AND INNOVATIVE TRENDS IN SUSTAINABLE GROWTH - STRATEGY CHALLENGES FOR ECONOMIC AND SOCIAL POLICIES, PT 1, 2018, : 277 - 288
  • [8] De-risking biologics development through advanced mass spectrometry approaches
    Chadwick, Jennifer S.
    [J]. Pharmaceutical Technology, 2019, 2019 (04)
  • [9] De-risking Biologics Development Through Advanced Mass Spectroscopy Approaches
    Chadwick, Jennifer S.
    [J]. BIOPHARM INTERNATIONAL, 2019, 32 (08) : 42 - 45
  • [10] Target safety assessments and their role in de-risking drug discovery: NaV1.7 as an example
    Eades, Lauren
    Sadler, Claire
    Knight, Richard
    Morton, Michael
    Roberts, Ruth
    [J]. TOXICOLOGY LETTERS, 2017, 280 : S224 - S225
12345